I attended the Marketing Authorization Seminar 2024 held in Helsinki, organized by the Pharmacy Learning Center. The event brought together experts from the pharmaceutical field to discuss current topics and future perspectives.
A wide range of specialists from various sectors presented at the seminar, including representatives from Fimea, industry, wholesale, consulting services, and university. The program was divided into four sections: Sustainability Aspects of Medicinal Products, EU Pharmaceutical Legislation, Looking to the Future, and Updates from Fimea.
Throughout the day, many relevant topics were addressed, such as environmental requirements for medicinal products, electronic product information, antibiotic resistance, and the implementation of the medicinal product database (PMS). The use of artificial intelligence and the opportunities it presents were highlighted in several presentations.
Fimea’s presentations covered various current issues, one of which was the update of the Finnish blue box requirements regarding package leaflets. Fimea reminded that these text changes can be implemented alongside the next clinical text update variation.
Attending the seminar was extremely rewarding, and I warmly recommend the event to all regulatory affairs professionals as well as those interested in regulatory matters. The seminar provides an excellent opportunity to network and stay updated on current topics in the field.
/Hanna
